Immunology

Dendritic Cells Vaccine May Spur Tumor Resistance

Published in Cancer Weekly, February 22nd, 2000

A vaccine of tumor peptide-pulsed bone marrow-derived dendritic cells may have promise for inducing tumor resistance.

Grzegorz Dworacki and colleagues evaluated the efficacy of vaccines consisting of tumor peptide-pulsed bone marrow (BM)-derived dendritic cells (DC) generated in the presence of FBS or BALB/c mouse serum (NMS) in the BALB/c Meth A tumor model.

They reported their findings at the Proceedings of the 1999 American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer New Drugs Meeting, held November 16-19, 1999, in Washington, DC. Their study was titled "Murine non-pulsed...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-02-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry